account_id none on file
legal_name KALA BIO, Inc.
ticker KALA
cik 1479419
domain kalarx.com
linkedin_company_url https://www.linkedin.com/company/kala-pharmaceuticals
entry_point_account_id none on file
name KALA BIO Inc.
exchange Nasdaq
sector Health Care
hq Arlington, MA, United States
sector index/company/sector/health-care/
calls 0 filings 5 executives 6 family 0
why_nownone on file
callsnone on file
filings
General and administrative expenses consist primarily of salaries, benefits, stock-based compensation and travel expenses related to our executive, finance, human resources, legal, compliance, information technology and business development functions.
filing / Aug 19, 2026 / receipt
We closely monitor our monthly cash operating costs and adjust discretionary spending as circumstances require. Net cash used in operating activities decreased to $4.4 million for the six months ended June 30, 2026, from $16.6 million for the six months ended June 30, 2025 .
filing / Aug 19, 2026 / receipt
The decrease was primarily driven by a decrease in KPI-012 clinical development costs following our discontinuation of our MSC-S platform and the decrease in personnel and facilities expenses after workforce reductions .
filing / Aug 19, 2026 / receipt
General and administrative expenses consist primarily of salaries, benefits, stock-based compensation and travel expenses related to our executive, finance, human resources, legal, compliance, information technology and business development functions.
filing / May 15, 2026 / receipt
The decrease was primarily driven by a decrease in KPI-012 clinical development costs following our discontinuation of our MSC-S platform and the decrease in personnel and facilities expenses after workforce reductions.
filing / May 15, 2026 / receipt
executives
| Andrew Ian Koven | director | - | receipt |
| Avi Minkowitz | Chief Executive Officer | - | receipt |
| David Lazar | Chief Executive Officer | - | receipt |
| Gregory Perry | director | - | receipt |
| Mark Iwicki | President | - | receipt |
| Todd Bazemore | Chief Executive Officer | - | receipt |
familynone on file
upcoming
| 2026-11-18 | earnings call | scheduled |
changes
| 2026-02-05 | Chief Executive Officer, appointed | sec_8k |
| 2025-11-25 | Chief Executive Officer, appointed | sec_8k |
| 2025-09-02 | Chief Executive Officer, appointed | sec_8k |
| 2021-12-20 | President and Chief Operating Officer, appointed | sec_8k |
| 2018-03-05 | director, appointed | sec_8k |
| 2017-11-13 | Chief Operating Officer, appointed | sec_8k |
| 2017-10-02 | director, appointed | sec_8k |
| 2017-08-11 | President, appointed | sec_8k |
mcp_package_hint
slug kala-bio-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$